Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis

Jingzhong Ouyang,1,* Zhengzheng Wang,1,* Kun Yuan,2,* Yi Yang,3,4 Yanzhao Zhou,1 Qingjun Li,1 Nanmu Yang,1 Haitao Zhao,5 Hong Zhao,3,4 Jinxue Zhou1 1Department of Hepatobiliary and Pancreatic Surgery, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou,...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ouyang J, Wang Z, Yuan K, Yang Y, Zhou Y, Li Q, Yang N, Zhao H, Zhou J
Format:	Artigo
Idioma:	Inglês
Publicat:	Dove Medical Press 2023-09-01
Col·lecció:	Journal of Hepatocellular Carcinoma
Matèries:	hepatocellular carcinoma postoperative adjuvant therapy lenvatinib pd-1 antibody efficacy safety
Accés en línia:	https://www.dovepress.com/adjuvant-lenvatinib-plus-pd-1-antibody-for-hepatocellular-carcinoma-wi-peer-reviewed-fulltext-article-JHC
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!